# Scalable Agentic Reasoning for Designing Biologics Targeting Intrinsically Disordered Proteins

arXiv: https://arxiv.org/abs/2512.15930 · HTML: https://mlsanity.com/paper/2512.15930/

## Key facts

- No citing papers in the map yet (data through 14 Oct 2026).
- Placed in Medical and scientific domain agents, one of 16 directions in LLM agents and tool use.
- Builds on 11 of its 69 references that are in the map.
- First posted on arXiv 17 Dec 2025.

## Placed in

- LLM agents and tool use / [Medical and scientific domain agents](https://mlsanity.com/agents/medical-and-scientific-domain-agents/)

## Builds on (most cited first, 11 of 11)

- [Direct Preference Optimization: Your Language Model is Secretly a Reward Model](https://mlsanity.com/paper/2305.18290/) (2023)
- [Billion-scale similarity search with GPUs](https://mlsanity.com/paper/1702.08734/) (2017)
- [Domain-Specific Language Model Pretraining for Biomedical Natural Language Processing](https://mlsanity.com/paper/2007.15779/) (2020)
- [ChemCrow: Augmenting large-language models with chemistry tools](https://mlsanity.com/paper/2304.05376/) (2023)
- [OpenAlex: A fully-open index of scholarly works, authors, venues, institutions, and concepts](https://mlsanity.com/paper/2205.01833/) (2022)
- [L2 Regularization versus Batch and Weight Normalization](https://mlsanity.com/paper/1706.05350/) (2017)
- [Kosmos: An AI Scientist for Autonomous Discovery](https://mlsanity.com/paper/2511.02824/) (2025)
- [Parsl: Pervasive Parallel Programming in Python](https://mlsanity.com/paper/1905.02158/) (2019)
- [Empowering Scientific Workflows with Federated Agents](https://mlsanity.com/paper/2505.05428/) (2025)
- [HiPerRAG: High-Performance Retrieval Augmented Generation for Scientific Insights](https://mlsanity.com/paper/2505.04846/) (2025)
- [BioNeMo Framework: a modular, high-performance library for AI model development in drug discovery](https://mlsanity.com/paper/2411.10548/) (2024)

## Abstract (arXiv)

Intrinsically disordered proteins (IDPs) represent crucial therapeutic targets due to their significant role in disease -- approximately 80% of cancer-related proteins contain long disordered regions -- but their lack of stable secondary/tertiary structures makes them "undruggable". While recent computational advances, such as diffusion models, can design high-affinity IDP binders, translating these to practical drug discovery requires autonomous systems capable of reasoning across complex conformational ensembles and orchestrating diverse computational tools at scale.To address this challenge, we designed and implemented StructBioReasoner, a scalable multi-agent system for designing biologics that can be used to target IDPs. StructBioReasoner employs a novel tournament-based reasoning framework where specialized agents compete to generate and refine therapeutic hypotheses, naturally distributing computational load for efficient exploration of the vast design space. Agents integrate domain knowledge with access to literature synthesis, AI-structure prediction, molecular simulations, and stability analysis, coordinating their execution on HPC infrastructure via an extensible federated agentic middleware, Academy. We benchmark StructBioReasoner across Der f 21 and NMNAT-2 and demonstrate that over 50% of 787 designed and validated candidates for Der f 21 outperformed the human-designed reference binders from literature, in terms of improved binding free energy. For the more challenging NMNAT-2 protein, we identified three binding modes from 97,066 binders, including the well-studied NMNAT2:p53 interface. Thus, StructBioReasoner lays the groundwork for agentic reasoning systems for IDP therapeutic discovery on Exascale platforms.